Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Down 4.7% – What’s Next?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) was down 4.7% during mid-day trading on Tuesday . The company traded as low as $289.23 and last traded at $290.00. Approximately 818 shares traded hands during trading, an increase of 5,282% from the average daily volume of 15 shares. The stock had previously closed at $304.15.

Bio-Rad Laboratories Price Performance

The company’s 50 day moving average price is $286.00 and its 200 day moving average price is $289.54. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. The company has a market cap of $7.76 billion, a price-to-earnings ratio of 47.78 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO.B) last announced its earnings results on Thursday, April 30th. The company reported $1.89 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.